| Literature DB >> 34484559 |
Wei Peng1,2,3,4, Liyang Wan2,3,4,5, Zixiang Luo1,2,3,4, Yong Xie1,2,3,4, Yudong Liu1,2,3,4, Tingmo Huang2,3,4,5, Hongbin Lu2,3,4,5, Jianzhong Hu1,2,3,4.
Abstract
Traumatic spinal cord injury (SCI) is a devastating disease of the central nervous system with long-term disability and high mortality worldwide. Revascularization following SCI provides nutritional supports to rebuild and maintain the homeostasis of neuronal networks, and the subsequent promotion of angiogenesis is beneficial for functional recovery. Oxidative stress drastically produced following SCI has been contributed to endothelial dysfunction and the limited endogenous repair of microvasculature. Recently, exosomes, being regarded as potential therapeutic candidates for many kinds of diseases, have attracted great attentions due to its high bioavailability, safety, and stability. Microglia have been reported to exhibit proangiogenic function and guide the forming of vasculature during tissue repair. However, the specific role of microglia-derived exosomes (MG-Exos) played in SCI is still largely unknown. In the present study, we aimed to evaluate whether MG-Exos could protect spinal cord microvascular endothelial cells (SCMECs) against the toxic effects of oxidative stress, thus promote SCMECs' survival and function. We also investigated the protective effects of MG-Exos in the mouse model of SCI to verify their capability. Our results demonstrated that MG-Exo treatment significantly decreased the level of oxidative stress (ROS), as well as did the protein levels of NOX2 when bEnd.3 cells were exposed to H2O2-induced oxidative stress in vitro and in vivo. Functional assays showed that MG-Exos could improve the survival and the ability of tube formation and migration in H2O2-induced bEnd.3 in vitro. Moreover, MG-Exos exhibited the positive effects on vascular regeneration and cell proliferation, as well as functional recovery, in the mouse model of SCI. Mechanically, the keap1/Nrf2/HO-1 signaling pathway was also investigated in order to unveil its molecular mechanism, and the results showed that MG-Exos could increase the protein levels of Nrf2 and HO-1 via inhibiting the keap1; they also triggered the expression of its downstream antioxidative-related genes, such as NQo1, Gclc, Cat, and Gsx1. Our findings indicated that MG-Exos exerted an antioxidant effect and positively modulated vascular regeneration and neurological functional recovery post-SCI by activating keap1/Nrf2/HO-1 signaling.Entities:
Mesh:
Year: 2021 PMID: 34484559 PMCID: PMC8413072 DOI: 10.1155/2021/1695087
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
All primer sequences used for qRT-PCR.
|
| Forward primer | ATGGGAGGTGGTCGAATCTGA |
| Reverse primer | GCCTTCCTTATACGCCAGAGATG | |
|
| Forward primer | GGGGTGACGAGGTGGAGTA |
| Reverse primer | GTTGGGGTTTGTCCTCTCCC | |
|
| ||
|
| Forward primer | AGCGACCAGATGAAGCAGTG |
| Reverse primer | TCCGCTCTCTGTCAAAGTGTG | |
|
| ||
|
| Forward primer | CTTCCCTCCCTTCGGATCG |
| Reverse primer | GTCCACAGAGATGCAGTGAAA | |
Figure 1Identification of microglia and MG-Exos. (a) The morphology of microglia. Scale bars = 100 μm. (b) Representative immunofluorescence images of microglia. Iba-1 (red) and F4/80 (green), scale bars = 100 μm. (c) Flow cytometry analysis of the cell markers of microglia. The isotype controls are illustrated as blue dashed curves, and the test samples are illustrated as solid red curves. (d) Representative images of MG-Exo morphology detected by transmission electron microscopy (TEM). Scale bar = 100 nm. Red arrows indicate exosomes. (e) Size distribution assessed by nanoparticle tracking analysis (NTA). (f) Western blotting analysis of specific exosomal surface markers.
Figure 2MG-Exos were internalized into endothelia cells and inhibited ROS in vivo and in vitro. (a) Fluorescence microscopy analysis of PKH67-labeled MG-Exos taken up by bEnd.3. Scale bar = 50 μm. (b) The ROS level of the epicenter of the spinal cord's injury area per group was detected by the DCFH-DA assay throughout the 14-day period post-SCI. (c) Representative fluorescence images of the ROS levels of bEnd.3 treated with H2O2 plus MG-Exos or Vehicle. DCFH-DA (green) and nuclei (blue); scale bar = 100 μm. (d) Quantitative analysis of the number of DCFH-DA positive cells in (c). (e) Western blotting analysis of the protein levels of NOX2 in bEnd.3 treated with MG-Exos or Vehicle when exposed to H2O2-induced oxidative stress. The data are presented as the means ± SD; n = 6 per group. ∗p < 0.05 and ∗∗p < 0.01 compared with different treatment groups.
Figure 3MG-Exos promote survival and function of endothelial cells in vitro. (a) CCK-8 analysis of the survival rate of bEnd.3 treated with MG-Exos or Vehicle when exposed to H2O2-induced oxidative stress. (b) Representative images of bEnd.3 tube formation in vitro after H2O2 plus Vehicle or MG-Exo treatment. Scale bar = 50 μm. (c–e) Quantitative evaluation of the total tube length, total branching points, and total loops in (b). (f) Representative images of bEnd.3 migration in the H2O2 plus Vehicle or MG-Exo treatment groups in the scratch assay. Scale bar = 250 μm. (g) Quantification of the percentage of migration area in (f). (h) Representative images of transwell experiment in the H2O2 plus Vehicle or MG-Exo treatment groups. Scale bar = 100 μm. (i) Quantitative evaluation of the number of migration cells in (h). The data are presented as the means ± SD; n = 6 per group. ∗p < 0.05 and ∗∗p < 0.01 compared with different treatment groups.
Figure 4MG-Exos promote vascular regeneration post-SCI in vivo. (a) Representative immunofluorescence images of CD31 blood vessels in the epicenter of spinal cord's injury area in each group at 7 days post-SCI. CD31 (green) and nuclei (blue); scale bar = 200 μm and 50 μm (enlarged view). (b) Quantitative evaluation of the area vessels in (a). (c) Representative immunofluorescence images of CD31 (red) and ki67 (green) blood vessels in the mouse's spinal cord in each group at 7 days post-SCI. Scale bars = 200 μm and 50 μm (enlarged view). White arrows indicate CD31+ki67+ cells. (d) Quantification of the number of CD31 and ki67 double-positive cells in (c). The data are presented as the means ± SD; n = 6 per group. ∗p < 0.05 and ∗∗p < 0.01 compared with different treatment groups.
Figure 5MG-Exos improve spinal functional recovery after SCI. (a) Representative H&E staining of the longitudinal epicenter injury of spinal cord in each group at 28 days post-SCI. Scale bar = 1 mm. (b) Quantification of the lesion area in (a). (c) Distribution of the BMS scores per group after SCI throughout the 28-day period. (d) Distribution of the BMS subscores per group at 0, 1, 3, 7, 14, 21, and 28 days post-SCI. (e) Representative electrophysiological traces in each group at 28 days post-SCI. (f, g) Quantification of the amplitude and latent period of MEPs in (e). The data are presented as the means ± SD; n = 6 per group. ∗p < 0.05 and ∗∗p < 0.01 compared with different treatment groups.
Figure 6MG-Exos protect endothelia cells against the oxidative effects by modulating the keap1/Nrf2/HO-1 signaling pathway. (a) Representative immunofluorescence images of the Nrf2's expression of bEnd.3 after Vehicle or MG-Exo treatment when exposed to H2O2-induced oxidative stress. Scale bar = 100 μm. (b) Quantification of mean fluorescence intensity (MFI) in (a). (c) Western blotting analysis of the protein levels of keap1, Nrf2, and HO-1 in H2O2 plus Vehicle or MG-Exo treatment groups. (d–g) qPCR verification of the mRNA levels of downstream antioxidative-related genes including NQo1, Gclc, Cat, and Gsx1 per group when exposed to H2O2-induced oxidative stress. The data are presented as the means ± SD; n = 6 per group. ∗p < 0.05 and ∗∗p < 0.01 compared with different treatment groups.